Annual FCF
-$30.81 M
-$3.03 M-10.89%
September 30, 2024
Summary
- As of February 7, 2025, AVXL annual free cash flow is -$30.81 million, with the most recent change of -$3.03 million (-10.89%) on September 30, 2024.
- During the last 3 years, AVXL annual FCF has fallen by -$428.00 thousand (-1.41%).
- AVXL annual FCF is now -258824.37% below its all-time high of -$11.90 thousand, reached on September 30, 2004.
Performance
AVXL Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$6.66 M
-$1.48 M-28.53%
September 30, 2024
Summary
- As of February 7, 2025, AVXL quarterly free cash flow is -$6.66 million, with the most recent change of -$1.48 million (-28.53%) on September 30, 2024.
- Over the past year, AVXL quarterly FCF has dropped by -$1.48 million (-28.53%).
- AVXL quarterly FCF is now -24668.27% below its all-time high of $27.10 thousand, reached on June 30, 2006.
Performance
AVXL Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$30.81 M
-$809.00 K-2.70%
September 30, 2024
Summary
- As of February 7, 2025, AVXL TTM free cash flow is -$30.81 million, with the most recent change of -$809.00 thousand (-2.70%) on September 30, 2024.
- Over the past year, AVXL TTM FCF has dropped by -$809.00 thousand (-2.70%).
- AVXL TTM FCF is now -2800990.91% below its all-time high of -$1100.00, reached on December 31, 2004.
Performance
AVXL TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
AVXL Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.9% | -28.5% | -2.7% |
| 3 y3 years | -1.4% | +13.3% | -1.4% |
| 5 y5 years | -66.3% | +13.3% | -1.4% |
AVXL Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -27.1% | at low | -90.2% | +42.9% | -27.1% | +5.1% |
| 5 y | 5-year | -66.3% | at low | -90.2% | +42.9% | -75.4% | +5.1% |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +42.9% | <-9999.0% | +5.1% |
Anavex Life Sciences Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | -$30.81 M(+10.9%) | -$6.66 M(+28.5%) | -$30.81 M(+2.7%) |
| Jun 2024 | - | -$5.18 M(-55.6%) | -$30.00 M(-7.6%) |
| Mar 2024 | - | -$11.66 M(+59.3%) | -$32.48 M(+10.8%) |
| Dec 2023 | - | -$7.32 M(+25.1%) | -$29.31 M(+5.5%) |
| Sep 2023 | -$27.79 M(+14.6%) | -$5.85 M(-23.6%) | -$27.79 M(+6.9%) |
| Jun 2023 | - | -$7.65 M(-9.8%) | -$25.98 M(+2.4%) |
| Mar 2023 | - | -$8.49 M(+46.5%) | -$25.38 M(-4.3%) |
| Dec 2022 | - | -$5.79 M(+43.3%) | -$26.53 M(+9.5%) |
| Sep 2022 | -$24.24 M(-20.2%) | -$4.04 M(-42.7%) | -$24.24 M(-13.0%) |
| Jun 2022 | - | -$7.05 M(-26.8%) | -$27.87 M(-1.6%) |
| Mar 2022 | - | -$9.64 M(+175.3%) | -$28.34 M(+8.9%) |
| Dec 2021 | - | -$3.50 M(-54.4%) | -$26.01 M(-14.4%) |
| Sep 2021 | -$30.38 M(+42.7%) | -$7.67 M(+2.0%) | -$30.38 M(+4.9%) |
| Jun 2021 | - | -$7.52 M(+2.8%) | -$28.96 M(+13.6%) |
| Mar 2021 | - | -$7.32 M(-7.0%) | -$25.49 M(+8.8%) |
| Dec 2020 | - | -$7.87 M(+25.8%) | -$23.43 M(+10.1%) |
| Sep 2020 | -$21.29 M(+14.9%) | -$6.25 M(+54.7%) | -$21.29 M(+21.2%) |
| Jun 2020 | - | -$4.04 M(-23.2%) | -$17.57 M(-16.4%) |
| Mar 2020 | - | -$5.26 M(-8.1%) | -$21.02 M(+4.6%) |
| Dec 2019 | - | -$5.73 M(+125.9%) | -$20.09 M(+8.4%) |
| Sep 2019 | -$18.53 M(+47.2%) | -$2.53 M(-66.2%) | -$18.53 M(-7.6%) |
| Jun 2019 | - | -$7.50 M(+73.2%) | -$20.05 M(+37.0%) |
| Mar 2019 | - | -$4.33 M(+4.1%) | -$14.63 M(+11.5%) |
| Dec 2018 | - | -$4.16 M(+2.6%) | -$13.12 M(+4.3%) |
| Sep 2018 | -$12.58 M(+39.5%) | -$4.05 M(+94.1%) | -$12.58 M(+17.4%) |
| Jun 2018 | - | -$2.09 M(-26.0%) | -$10.72 M(-7.6%) |
| Mar 2018 | - | -$2.82 M(-22.1%) | -$11.61 M(+22.4%) |
| Dec 2017 | - | -$3.62 M(+65.2%) | -$9.48 M(+5.2%) |
| Sep 2017 | -$9.02 M(-2.4%) | -$2.19 M(-26.3%) | -$9.02 M(+3.8%) |
| Jun 2017 | - | -$2.97 M(+326.3%) | -$8.69 M(+9.5%) |
| Mar 2017 | - | -$697.70 K(-77.9%) | -$7.94 M(-13.2%) |
| Dec 2016 | - | -$3.15 M(+69.2%) | -$9.14 M(-1.0%) |
| Sep 2016 | -$9.24 M(+118.5%) | -$1.86 M(-16.2%) | -$9.24 M(+4.9%) |
| Jun 2016 | - | -$2.22 M(+16.9%) | -$8.81 M(+9.9%) |
| Mar 2016 | - | -$1.90 M(-41.4%) | -$8.01 M(+18.2%) |
| Dec 2015 | - | -$3.25 M(+126.5%) | -$6.78 M(+60.4%) |
| Sep 2015 | -$4.23 M(+58.8%) | -$1.43 M(+0.2%) | -$4.23 M(+13.9%) |
| Jun 2015 | - | -$1.43 M(+113.4%) | -$3.71 M(+14.5%) |
| Mar 2015 | - | -$670.30 K(-3.3%) | -$3.24 M(+11.1%) |
| Dec 2014 | - | -$693.10 K(-24.5%) | -$2.92 M(+9.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2014 | -$2.66 M(+242.4%) | -$917.50 K(-4.4%) | -$2.66 M(+19.4%) |
| Jun 2014 | - | -$960.00 K(+176.3%) | -$2.23 M(+71.3%) |
| Mar 2014 | - | -$347.50 K(-20.5%) | -$1.30 M(+20.1%) |
| Dec 2013 | - | -$437.30 K(-9.7%) | -$1.08 M(+39.3%) |
| Sep 2013 | -$777.60 K(-54.1%) | -$484.50 K(+1404.7%) | -$777.60 K(+42.7%) |
| Jun 2013 | - | -$32.20 K(-75.1%) | -$545.00 K(-27.5%) |
| Mar 2013 | - | -$129.30 K(-1.7%) | -$751.50 K(+2.1%) |
| Dec 2012 | - | -$131.60 K(-47.8%) | -$736.40 K(-56.5%) |
| Sep 2012 | -$1.69 M(-55.5%) | -$251.90 K(+5.5%) | -$1.69 M(-28.4%) |
| Jun 2012 | - | -$238.70 K(+109.0%) | -$2.36 M(-29.0%) |
| Mar 2012 | - | -$114.20 K(-89.5%) | -$3.33 M(-12.5%) |
| Dec 2011 | - | -$1.09 M(+17.9%) | -$3.81 M(+0.1%) |
| Sep 2011 | -$3.80 M(-17.3%) | -$922.60 K(-23.5%) | -$3.80 M(-16.3%) |
| Jun 2011 | - | -$1.21 M(+104.8%) | -$4.54 M(+2.4%) |
| Mar 2011 | - | -$588.90 K(-45.7%) | -$4.44 M(-9.4%) |
| Dec 2010 | - | -$1.08 M(-34.8%) | -$4.90 M(+6.6%) |
| Sep 2010 | -$4.60 M(+64.4%) | -$1.66 M(+51.4%) | -$4.59 M(+17.7%) |
| Jun 2010 | - | -$1.10 M(+4.6%) | -$3.90 M(-2.1%) |
| Mar 2010 | - | -$1.05 M(+34.7%) | -$3.98 M(+20.5%) |
| Dec 2009 | - | -$780.00 K(-19.7%) | -$3.31 M(+18.3%) |
| Sep 2009 | -$2.80 M(+13.0%) | -$971.30 K(-17.8%) | -$2.79 M(+12.5%) |
| Jun 2009 | - | -$1.18 M(+216.2%) | -$2.48 M(+28.9%) |
| Mar 2009 | - | -$373.60 K(+39.2%) | -$1.93 M(-6.8%) |
| Dec 2008 | - | -$268.30 K(-59.3%) | -$2.07 M(-16.5%) |
| Sep 2008 | -$2.48 M(+661.1%) | -$659.90 K(+5.7%) | -$2.48 M(+32.0%) |
| Jun 2008 | - | -$624.40 K(+21.4%) | -$1.88 M(+29.0%) |
| Mar 2008 | - | -$514.40 K(-24.0%) | -$1.45 M(+46.3%) |
| Dec 2007 | - | -$676.40 K(+1025.5%) | -$993.90 K(+205.5%) |
| Sep 2007 | -$325.20 K(+903.7%) | -$60.10 K(-70.4%) | -$325.30 K(+6.1%) |
| Jun 2007 | - | -$202.90 K(+272.3%) | -$306.50 K(+300.7%) |
| Mar 2007 | - | -$54.50 K(+598.7%) | -$76.50 K(+95.2%) |
| Dec 2006 | - | -$7800.00(-81.1%) | -$39.20 K(+20.6%) |
| Sep 2006 | -$32.40 K(-47.0%) | -$41.30 K(-252.4%) | -$32.50 K(+177.8%) |
| Jun 2006 | - | $27.10 K(-257.6%) | -$11.70 K(-69.8%) |
| Mar 2006 | - | -$17.20 K(+1463.6%) | -$38.80 K(-36.4%) |
| Dec 2005 | - | -$1100.00(-94.6%) | -$61.00 K(0.0%) |
| Sep 2005 | -$61.10 K(+413.4%) | -$20.50 K(<-9900.0%) | -$61.00 K(+50.6%) |
| Jun 2005 | - | $0.00(-100.0%) | -$40.50 K(0.0%) |
| Mar 2005 | - | -$39.40 K(+3481.8%) | -$40.50 K(+3581.8%) |
| Dec 2004 | - | -$1100.00 | -$1100.00 |
| Sep 2004 | -$11.90 K | - | - |
FAQ
- What is Anavex Life Sciences annual free cash flow?
- What is the all time high annual FCF for Anavex Life Sciences?
- What is Anavex Life Sciences annual FCF year-on-year change?
- What is Anavex Life Sciences quarterly free cash flow?
- What is the all time high quarterly FCF for Anavex Life Sciences?
- What is Anavex Life Sciences quarterly FCF year-on-year change?
- What is Anavex Life Sciences TTM free cash flow?
- What is the all time high TTM FCF for Anavex Life Sciences?
- What is Anavex Life Sciences TTM FCF year-on-year change?
What is Anavex Life Sciences annual free cash flow?
The current annual FCF of AVXL is -$30.81 M
What is the all time high annual FCF for Anavex Life Sciences?
Anavex Life Sciences all-time high annual free cash flow is -$11.90 K
What is Anavex Life Sciences annual FCF year-on-year change?
Over the past year, AVXL annual free cash flow has changed by -$3.03 M (-10.89%)
What is Anavex Life Sciences quarterly free cash flow?
The current quarterly FCF of AVXL is -$6.66 M
What is the all time high quarterly FCF for Anavex Life Sciences?
Anavex Life Sciences all-time high quarterly free cash flow is $27.10 K
What is Anavex Life Sciences quarterly FCF year-on-year change?
Over the past year, AVXL quarterly free cash flow has changed by -$1.48 M (-28.53%)
What is Anavex Life Sciences TTM free cash flow?
The current TTM FCF of AVXL is -$30.81 M
What is the all time high TTM FCF for Anavex Life Sciences?
Anavex Life Sciences all-time high TTM free cash flow is -$1100.00
What is Anavex Life Sciences TTM FCF year-on-year change?
Over the past year, AVXL TTM free cash flow has changed by -$809.00 K (-2.70%)